upgrad buy valuat atop
upgrad buy rux cream cash flow outlook posit
follow posit data trial ruxolitinib cream atop dermat ad see
note conduct payor doctor check affirm view
ruxolitinib cream could pois find signific use second-lin topic agent
mild-to-moder patient atop dermat see given recent
move overal equiti market investor possibl start posit
toward defens invest view compani strong cash flow
jakafi franchis potenti increas revenu stream near term limit need
financ particularli attract estim chang still
model peak jakafi sale assum risk-adjust rux cream peak
upgrad buy po remain see page detail
doctor payor check affirm bullish view rux ad
follow posit trial spoke two doctor four payor repres
understand potenti usag product consist previou check
doctor one academ one privat practic total ad patient treat annual
cite need topic therapi topic steroid-prescrib mild-to-
moder pt fail topic steroid calcineurin inhibitor tacrolimu pimecrolimu
use though room improv topic agent term
efficaci toler doctor impress phase data
superior steroid reserv center around anticip difficulti
payor cover product spoke consult collect respons
cover nearli us live commerci coverag plan assum price line
eucrisa two payor expect singl step-through gener topic
presum steroid one payor expect doubl step-through two gener topic
product fourth requir step-through would anticip cover
product brand tier requir co-pay view feedback support
view rux cream wide use second line therapi gener
steroid downsid risk slow launch rux cream competit out-
year dcf
full definit iqmethod sm measur see page
bofa secur seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
incyt corpor biotechnolog
compani develop oral topic treatment
oncolog dermatolog indic
compani main asset jakafi mf pv
prepar launch two oncolog
medic also late stage
develop ruxolitinib cream
treatment ad vitiligo addit
rate buy view jakafi addit
revenu stream provid high valuat floor
earli stage pipelin littl clinic data
larg indic command larg amount
po consist jakafi/jakavi ruxolitinib
cream pemigatinib olumi royalti iclusig
capmatinib royalti pipelin remaind net cash appli wacc
commercial-stag asset late-stag clinic pipelin
upsid risk po posit data clinic trial pipelin
better expect result market asset
downsid risk po failur jakafi ruxolitinib cream meet
estim busi develop event investor view neg neg
data clinic trial
tazeen ahmad herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
qualiti earn
iqmethod smi set bofa global research standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa global research
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
